文献速递糖尿病骨质疏松与钙磷/甲状旁腺性腺与生殖内分泌

睾酮治疗对合并2型糖尿病的性腺功能减退男性骨量与骨转换的影响

Testosterone Therapy Effects on Bone Mass and Turnover in Hypogonadal Men with Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本研究为单臂开放标签临床试验,纳入105名平均晨间睾酮<300 ng/dL的性腺功能减退男性,每2周肌注环戊丙酸睾酮200 mg共18个月。结果显示,合并2型糖尿病者较非糖尿病者骨钙素升高更明显,腰椎面积骨密度增加,但胫骨体积骨密度降低而骨矿物含量保持。结论认为睾酮治疗对合并2型糖尿病的性腺功能减退男性骨骼健康改善更大。

要点

  • 睾酮治疗18个月后,合并2型糖尿病者骨钙素升高更显著,提示成骨细胞活性增加。
  • 合并2型糖尿病者腰椎面积骨密度增加,胫骨总横截面积及骨膜、骨内膜周长增加。
  • 合并2型糖尿病者胫骨体积骨密度降低,但骨矿物含量保持。

核心结论

  • 睾酮治疗对合并2型糖尿病的性腺功能减退男性骨骼健康的改善程度大于非糖尿病性腺功能减退男性。

研究设计与样本

  • 单臂、开放标签临床试验(NCT01378299),纳入105名40-74岁、平均晨间睾酮<300 ng/dL的性腺功能减退男性,其中49例合并2型糖尿病,56例非2型糖尿病。
  • 受试者每2周肌内注射环戊丙酸睾酮200 mg,持续18个月。

主要发现

  • 治疗18个月后,两组循环睾酮和雌二醇水平无差异。
  • 合并2型糖尿病者较非2型糖尿病者骨钙素升高更明显(P < .01),反映成骨细胞活性增加。
  • 合并2型糖尿病者腰椎面积骨密度增加(P < .05),胫骨38%部位总横截面积增加(P < .01),骨膜和骨内膜周长均增加(P < .01)。
  • 合并2型糖尿病者胫骨体积骨密度降低(P < .01),但骨矿物含量保持(P = .01)。
  • 两组HbA1c或体成分变化相似。

临床怎么用

  • 对于合并2型糖尿病的性腺功能减退男性,睾酮治疗可能带来更明显的骨骼健康获益。
  • 治疗期间需关注骨密度和骨转换指标的变化,尤其是胫骨体积骨密度降低而骨矿物含量保持的现象。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Male hypogonadism is associated with low bone mineral density (BMD) and increased fragility fracture risk. Patients with type 2 diabetes (T2D) have relatively higher BMD, but greater fracture risk. OBJECTIVE: Evaluate the skeletal response to testosterone therapy in hypogonadal men with T2D compared with hypogonadal men without T2D. METHODS: Single arm, open-label clinical trial (NCT01378299) involving 105 men (40-74 years old), with average morning testosterone <300 ng/dL. Subjects were injected intramuscularly with testosterone cypionate (200 mg) every 2 weeks for 18 months. Testosterone and estradiol were assessed by liquid chromatography/mass spectrometry; serum C-terminal telopeptide of type I collagen (CTX), osteocalcin and sclerostin by enzyme-linked immunosorbent assay; glycated hemoglobin (HbA1c) by high-performance liquid chromatography, areal BMD (aBMD) and body composition by dual-energy x-ray absorptiometry; tibial volumetric BMD (vBMD) and bone geometry by peripheral quantitative computed tomography. RESULTS: Among our population of hypogonadal men, 49 had T2D and 56 were non-T2D. After 18 months of testosterone therapy, there were no differences in circulating testosterone and estradiol between the groups. Hypogonadal men with T2D had increased osteocalcin, reflecting increased osteoblast activity, compared with non-T2D men (P < .01). T2D men increased lumbar spine aBMD (P < .05), total area at 38% tibia (P < .01) and periosteal and endosteal circumferences at the same site (P < .01 for both). T2D men had reduced tibial vBMD (P < .01), but preserved bone mineral content (P = .01). Changes in HbA1c or body composition were similar between the 2 groups. CONCLUSION: Testosterone therapy results in greater improvements in the skeletal health of hypogonadal men with T2D than their nondiabetic counterparts.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Colleluori G, Aguirre L, Napoli N, et al. Testosterone Therapy Effects on Bone Mass and Turnover in Hypogonadal Men with Type 2 Diabetes. J Clin Endocrinol Metab. 2021. PMID: 33735389. doi:10.1210/clinem/dgab181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。